

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Corepharma, L.L.C.		04/09/2012	LIMITED LIABILITY COMPANY: NEW JERSEY
Corepharma, Inc.		04/09/2012	CORPORATION: DELAWARE
Corepharma Holdings, Inc.		04/09/2012	CORPORATION: DELAWARE
Amedra Pharmaceuticals LLC		04/09/2012	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	General Electric Capital Corporation		
Street Address:	500 West Monroe Street		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60661		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	3797506	ADRENACLICK	
Registration Number:	3311867	TWINJECT	
Registration Number:	3101978	TWINJECT	
Registration Number:	3449047	TWINJECT AUTO-INJECTOR	
Registration Number:	2992781	TWINJECT	
CORRESPONDENCE DATA			
Fax Number:	(404)443-5697		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	404-443-5702		
Email:	lallen@mcguirewoods.com		

OP \$140.00 3797506

Correspondent Name: Gerum Yilma, Esq.
Address Line 1: McGuireWoods LLP
Address Line 2: 1230 Peachtree Street N.E., Suite 2100
Address Line 4: Atlanta, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	2060236-0021 COREPHARMA
NAME OF SUBMITTER:	Latosha E. Allen
Signature:	/Latosha E. Allen/
Date:	04/11/2012

Total Attachments: 18

source=CorePharma - Intellectual Property Security Agreement #page1.tif
source=CorePharma - Intellectual Property Security Agreement #page2.tif
source=CorePharma - Intellectual Property Security Agreement #page3.tif
source=CorePharma - Intellectual Property Security Agreement #page4.tif
source=CorePharma - Intellectual Property Security Agreement #page5.tif
source=CorePharma - Intellectual Property Security Agreement #page6.tif
source=CorePharma - Intellectual Property Security Agreement #page7.tif
source=CorePharma - Intellectual Property Security Agreement #page8.tif
source=CorePharma - Intellectual Property Security Agreement #page9.tif
source=CorePharma - Intellectual Property Security Agreement #page10.tif
source=CorePharma - Intellectual Property Security Agreement #page11.tif
source=CorePharma - Intellectual Property Security Agreement #page12.tif
source=CorePharma - Intellectual Property Security Agreement #page13.tif
source=CorePharma - Intellectual Property Security Agreement #page14.tif
source=CorePharma - Intellectual Property Security Agreement #page15.tif
source=CorePharma - Intellectual Property Security Agreement #page16.tif
source=CorePharma - Intellectual Property Security Agreement #page17.tif
source=CorePharma - Intellectual Property Security Agreement #page18.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Intellectual Property Security Agreement”), dated as of April 9, 2012, is made by the Persons named on Schedule V hereto and signatory hereto (each a “Grantor” and, collectively, the “Grantors”), with offices at the locations set forth on Schedule IV hereto, in favor of **GENERAL ELECTRIC CAPITAL CORPORATION**, a Delaware corporation, acting in its capacity as Administrative Agent for the Lending Parties under the Amended and Restated Credit Agreement described below, with offices at 500 West Monroe Street, Chicago, Illinois 60661 (the “Administrative Agent”).

WITNESSETH:

WHEREAS, pursuant to that certain Amended and Restated Credit Agreement dated as of October 22, 2010 by and among CorePharma, L.L.C. (the “Borrower”), the other Credit Parties signatory thereto, the Lending Parties signatory thereto and General Electric Capital Corporation (collectively, the “Lending Parties”) (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented, extended replaced or otherwise modified, the “Credit Agreement”), the Lending Parties have agreed, subject to the terms and conditions provided therein, to make certain loans and other financial accommodations for the benefit of the Borrower and the other Grantors;

WHEREAS, Administrative Agent and the Lending Parties are willing to make the financial accommodations as provided for in the Credit Agreement, but only upon the condition, among others, that Borrower and each Guarantor (including the Grantors) shall have executed and delivered to the Administrative Agent, for itself and the ratable benefit of Lending Parties, that certain Borrower Security Agreement, that certain Holdings Security Agreement, that certain Parent Security Agreement or that certain Subsidiary Security Agreement, as applicable, each dated as of October 22, 2010 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, collectively, the “Security Agreements”);

WHEREAS, each Grantor has previously executed that certain Amended and Restated Intellectual Property Security Agreement dated as of October 22, 2010 (the “First IP Security Agreement”) and pursuant to the Credit Agreement and the Security Agreements, each Grantor is required to execute and deliver to Administrative Agent, for itself and the ratable benefit of the Lending Parties, this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

1. **Definitions.** All capitalized terms used but not otherwise defined herein have the meanings given to them in **Section 1.1** of the Credit Agreement.

2. **Grant of Security Interest.** To secure the prompt and complete payment and performance of all of the Obligations, each Grantor hereby grants, assigns, conveys, mortgages, pledges, hypothecates and transfers to Administrative Agent, for itself and the benefit of the Lending Parties, a Lien upon all of its right, title and interest of such Grantor in, to and under the following, whether presently existing or hereafter created or acquired (collectively, with respect to each Grantor, the “Intellectual Property Collateral”):

(a) all of its Patents including those referred to on Schedule I hereto and Patent Licenses to which it is a party;

(b) all of its Trademarks including those referred to on Schedule II hereto and Trademark Licenses to which it is a party;

(c) all of its Copyrights including those referred to on Schedule III hereto and Copyright Licenses to which it is a party;

(d) all reissues, continuations or extensions of the foregoing;

(e) all goodwill of the business connected with the use of, and symbolized by, each Patent, each Patent License, each Trademark, each Trademark License, each Copyright and each Copyright License; and

(f) all products and proceeds of the foregoing, including, without limitation, any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Patent or Patent licensed under any Patent License, (ii) injury to the goodwill associated with any Patent or any Patent licensed under any Patent License, (iii) infringement or dilution of any Trademark or Trademark licensed under any Trademark License, (iv) injury to the goodwill associated with any Trademark or any Trademark licensed under any Trademark License, (v) infringement or dilution of any Copyright or Copyright licensed under any Copyright License, and (vi) injury to the goodwill associated with any Copyright or any Copyright licensed under any Copyright License.

Notwithstanding anything in this Section to the contrary, the following shall not constitute “Intellectual Property Collateral” hereunder: any intent-to-use trademark application to the extent and for so long as creation by the Grantor of a security interest therein would result in the abandonment, invalidation or unenforceability thereof.

3. **Representations and Warranties.** Each Grantor represents and warrants to the Administrative Agent and the Lending Parties that such Grantor does not have any interest in, or title to, any Patent, registered Trademark or registered Copyright except as set forth in Schedule I, Schedule II and Schedule III, respectively, hereto, and as set forth in Schedule I, Schedule II and Schedule III, respectively, to the First IP Security Agreement.. This Intellectual Property Security Agreement is effective to create a valid and continuing Lien on and, upon the recording hereof by the United States Copyright Office and the United States Patent and Trademark Office, perfected Liens in favor of Administrative Agent (for the benefit of itself and the Lending Parties) on each Grantor’s Patents, Trademarks and Copyrights set forth in Schedule I, Schedule II and Schedule III, respectively, hereto, and such perfected Liens are enforceable as such as

against any and all creditors of and purchasers from any Grantor to the extent that recording in the United States Copyright Office and the United States Patent and Trademark Office is effective to do so and subject to the proviso in the next sentence. Upon recording of this Intellectual Property Security Agreement by the United States Copyright Office and the United States Patent and Trademark Office and the filing of appropriate financing statements in the jurisdictions listed on Schedule I to the Security Agreements, all action necessary or desirable to protect and perfect Administrative Agent's Lien on each Grantor's Patents, Trademarks or Copyrights shall have been duly taken; provided, however, that the subsequent recordation of this Intellectual Property Security Agreement in the U.S. Patent and Trademark Office and U.S. Copyright Office, as applicable, may be necessary to perfect the security interest of the Administrative Agent in issued registrations and applications for other U.S. Intellectual Property that are acquired by any Grantor after the date hereof, the registration of unregistered Copyrights in the U.S. Copyright Office may be required in order to perfect the Administrative Agent's Lien therein, and the taking of actions outside the United States may be required in order to perfect the Administrative Agent's Lien in Intellectual Property included in the Collateral which is protected under non-U.S. law.

4. **Covenants**. Each Grantor covenants and agrees with the Administrative Agent that from and after the date of this Intellectual Property Security Agreement and until the Commitment Termination Date:

(a) Grantors shall notify Administrative Agent immediately if they know or have reason to know that any material application or registration relating to any Patent, Trademark or Copyright (now or hereafter existing) may become abandoned or dedicated to the public, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court) regarding any Grantor's ownership of any Patent, Trademark or Copyright, its right to register the same, or to keep and maintain the same.

(b) Grantors shall provide Administrative Agent with written notice of any application filed by any Grantor, either by itself or through any agent, employee, licensee or designee, to register any Patent, Trademark or Copyright with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in the United States within ninety (90) days of such filing, and, upon request of Administrative Agent, such Grantor shall execute and deliver a supplement hereto as Administrative Agent may request to evidence Administrative Agent's Lien on such Patent, Trademark or Copyright, and the General Intangibles of such Grantor relating thereto or represented thereby.

(c) Grantors shall take all commercially reasonable actions necessary or requested by Administrative Agent to maintain and pursue each application, to obtain the relevant registration and to maintain the registration of each of the Patents, Trademarks and Copyrights (now or hereafter existing), including the filing of applications for renewal, affidavits of use, affidavits of noncontestability and opposition and interference and cancellation proceedings, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.

(d) In the event that any of the Intellectual Property Collateral is infringed upon, or misappropriated or diluted by a third party, such Grantor shall (1) comply with Section 5(a)(ix) of the Security Agreements and (2) unless such Grantor shall reasonably determine that such Intellectual Property Collateral is not material to the conduct of its business or operations, promptly take all commercially reasonable actions, including to sue to enjoin any such conduct and/or to recover any and all damages for such infringement, misappropriation or dilution.

5. **Security Agreement.** The security interests granted by each Grantor pursuant to this Intellectual Property Security Agreement are granted in conjunction with the security interest granted by each Grantor to Administrative Agent, on behalf of itself and the Lending Parties, pursuant to the Security Agreements. Each Grantor and Administrative Agent expressly agree that the security interests granted under this Intellectual Property Security Agreement and the Security Agreements in the Intellectual Property Collateral are intended to be treated as a single security interest for purposes of Article 9 of the Code and other applicable law. The exercise by the Administrative Agent or the Lending Parties of any rights or remedies with respect to any of the Intellectual Property Collateral shall be deemed to be an exercise of such rights or remedies in connection with both this Intellectual Property Security Agreement and the Security Agreements. In the event of any inconsistency between the terms and conditions of this Intellectual Property Security Agreement and the Security Agreements, then the terms and conditions of the Security Agreements shall prevail.

6. **Reinstatement.** This Intellectual Property Security Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any Grantor for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of any Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

7. **Notices.** Whenever it is provided herein that any notice, demand, request, consent, approval, declaration or other communication shall or may be given to or served upon any of the parties by any other party, or whenever any of the parties desires to give and serve upon any other party any communication with respect to this Intellectual Property Security Agreement, each such notice, demand, request, consent, approval, declaration or other communication shall be in writing and shall be given in the manner, and deemed received, as provided for in the Credit Agreement.

8. **Termination; Authorized Sales of Collateral.** Subject to Section 6 hereof, this Intellectual Property Security Agreement shall terminate upon the Commitment Termination Date. In the event any Grantor proposes to sell any of the Intellectual Property Collateral and such sale is permitted pursuant to the terms and conditions set forth in Section 7.8 of the Credit

Agreement, the Administrative Agent agrees, at the expense of such Grantor, to execute and deliver to such Grantor, prior to or contemporaneously with Grantor's receipt of the proceeds from such sale, such UCC-3 termination statements and other collateral property releases necessary to release the applicable Intellectual Property Collateral from the lien and security interest of the Administrative Agent.


9. **Governing Law.** THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF ILLINOIS. GRANTORS HEREBY SUBMIT TO THE NONEXCLUSIVE JURISDICTION OF THE FEDERAL AND/OR STATE COURTS SITTING IN COOK COUNTY, CITY OF CHICAGO, ILLINOIS FOR PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. GRANTORS IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH ANY OF THEM MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH OF THE PARTIES HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN **SECTION 11.3** OF THE CREDIT AGREEMENT. NOTHING IN THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]


IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer or other representative as of the date first set forth above.

GRANTORS:


COREPHARMA, L.L.C.

By: 
Name: ERNEST DE PAOLANTONIO
Title: CFO


COREPHARMA, INC.

By: 
Name: ERNEST DE PAOLANTONIO
Title: CFO

COREPHARMA HOLDINGS, INC.


By: 
Name: ERNEST DE PAOLANTONIO
Title: CFO

AMEDRA PHARMACEUTICALS LLC

By: 
Name: ERNEST DE PAOLANTONIO
Title: CFO

ACCEPTED AND ACKNOWLEDGED BY:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Kevin S. Kitz
Title: Duly Authorized Signatory

ACKNOWLEDGMENT OF GRANTORS

STATE OF NJ

COUNTY OF Monmouth

On this 29th day of March, 2012, before me personally appeared Ernest DePaolantonio, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of the following entities:

CorePharma, L.L.C.

CorePharma, Inc.

CorePharma Holdings, Inc.

Amedra Pharmaceuticals LLC

who being by me duly sworn did depose and say that he is the Authorized Person of said company, that the said instrument was signed on behalf of said company as authorized by its Board of Directors (or equivalent governing body) and that he acknowledged said instrument to be the free act and deed of said company.

Tara Sutton

Notary Public

{seal}

Tara Sutton
Notary Public
New Jersey

SCHEDULE I
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

Patents:

I. U.S. PATENT APPLICATIONS AND REGISTRATIONS:

II. FOREIGN PATENT APPLICATIONS AND REGISTRATIONS:

III. PATENT LICENSES:

All Patents owned by Washington Biotech Corporation and exclusively licensed to CorePharma, L.L.C. (as assignee of Shionogi, Inc.):

Title	Country	Serial #	Filing Date	Patent No.	Date of Issue/ Registration
Reloadable Automatic or Manual Emergency Injection System	United States	08/068,644	5/27/1993	5,358,489	10/25/1994

Reloadable Automatic or Manual Emergency Injection System	United States	08/243,641	5/16/1994	5,540,664	7/30/1996
Medicine Injection Syringe Constructions	United States	08/491,041	6/16/1995	5,833,669	11/10/1998
Reloadable Automatic or Manual Emergency Injection System	Canada	2163005	5/26/1994	2163005	1/11/2000
Reloadable Automatic or Manual Emergency Injection System	Portugal	9427660	5/26/1994	9427660	3/27/2000
Reloadable Automatic or Manual Emergency Injection System	Australia	7046294	5/26/1994	683901	3/19/1998
Reloadable Automatic or Manual Emergency Injection System	Poland	P311759	5/26/1994	176380	6/10/1998

Reloadable Automatic or Manual Emergency Injection System	Russia	95122674	5/26/1994	2131748	6/20/1999
Reloadable Automatic or Manual Emergency Injection System	United States	08/670,630	6/26/1996	5,665,071	9/9/1997
Modular Automatic or Manual Emergency Medicine Injection System	United States	08/687,508	7/30/1996	5,695,472	12/9/1997
Reloadable Automatic or Manual Emergency Injection System	Italy	85531BE2002	5/16/2002	700307	2/20/2002
Reloadable Automatic or Manual Emergency Injection System	Spain	949192553	5/27/1993	ES949192553	2/20/2002
Reloadable Automatic or Manual Emergency Injection System	Germany	69429918908	5/21/2002	69429918908	2/20/2002
Reloadable Automatic or Manual Emergency Injection System	France	949192553	5/26/1994	949192553	2/20/2002
Medicine Injection Devices and Methods	United States	11006382	12/6/2004	7,297,136	11/20/2007
Medicine Injection Devices and Methods	Taiwan	94131817	9/15/2005	I302841	11/11/2008
Kits Containing Medicine Injection Devices And Containers	United States	11/199,596	8/8/2005	7,905,352	3/15/2011
Methods and Apparatus for Delivering Epinephrine	United States	11/276,460	12/6/2004	7,621,891	11/24/2009
Methods and Apparatus for Delivering Epinephrine	United States	11/381,989	12/6/2004		
Medicine Injection Devices and Methods	EPO	058525270	11/22/2005		

Medicine Injection Devices and Methods	Canada	2589899	11/22/2005		
Medicine Injection Devices and Methods	United States	11/973,711	10/9/2007	7,927,303	4/19/2011
Medicine Injection Devices and Methods	Australia	2005314401	11/22/2005		
Medicine Injection Devices and Methods	Brazil	PI05184150	11/22/2005		
Medicine Injection Devices and Methods	China	200580041467X	11/22/2005	ZL200580041467X	2/16/2011
Medicine Injection Devices and Methods	Japan	2007544462	11/22/2005		
Medicine Injection Devices and Methods	Mexico	MX/a/2007/006250	11/22/2005		
Medicine Injection Devices and Methods	New Zealand	554828	11/22/2005	554828	11/6/2010
Medicine Injection Devices and Methods	Norway	20073488	11/22/2005		
Medicine Injection Devices and Methods	Russia	2007124153	11/22/2005		
Medicine Injection Devices and Methods	San Marino	SMAP200700023	11/22/2005	SMP200700023	1/2/2008
Medicine Injection Devices and Methods	South Africa	200704516	11/22/2005	200704516	10/29/2008
Apparatus and Methods for Injecting Medicines to a Desired Depth	United States	11/982,397	10/31/2007	7,931,618	4/26/2011
Medicine Injection Apparatuses	United States	12/569,529	9/29/2009		
Methods Performed by Medicine Injection Apparatuses	United States	12/569,737	9/29/2009		
Medicine Injection Apparatuses	United States	12/380,954	3/4/2009		
Medicine Injection Devices and Methods	Hong Kong	200580041467X	11/22/2005		
Medicine Injection Apparatuses	PCT	PCT/US2010/000682	3/4/2010		
Reloadable	United	949192553	5/26/1994	700307	2/20/2002

Automatic or Manual Emergency Injection System	Kingdom				
Medicine Injection Devices and Methods	China	2010101758009	5/5/2010		
Kits Containing Medicine Injection Devices and Containers	United States	13/012,649	1/24/2011		

SCHEDULE II
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks:

I. U.S. TRADEMARK APPLICATIONS AND REGISTRATIONS:

<u>Trademark</u>	<u>Serial Number</u>	<u>Reg. Number</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Owner</u>
Adrenacllick	77/818,149	3,797,506	September 2, 2009	June 1, 2010	CorePharma, L.L.C.
Twinject	78/764,430	3,311,867	December 1, 2005	October 16, 2007	CorePharma, L.L.C.
Twinject	78/470,999	3,101,978	August 20, 2004	June 6, 2006	CorePharma, L.L.C.
Twinject Auto-injector	77/307,888	3,449,047	October 18, 2007	June 17, 2008	CorePharma, L.L.C.
Twinject	76/309,722	2,992,781	September 6, 2001	September 6, 2005	CorePharma, L.L.C.

II. FOREIGN TRADEMARK APPLICATIONS AND REGISTRATIONS:

<u>Jurisdiction</u>	<u>Trademark</u>	<u>Application Number</u>	<u>Reg. Number</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Owner</u>
Canada	Twinject	1,154,855	TMA651953	October 4, 2002	October 31, 2005	CorePharma, L.L.C.
Canada	Twinpack	1,437,361	N/A	May 7, 2009 (published January 6, 2010)	N/A	CorePharma, L.L.C.

<u>Jurisdiction</u>	<u>Trademark</u>	<u>Application Number</u>	<u>Reg. Number</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Owner</u>
Canada	Adrenaclick	1,456,362	Pending	October 19, 2009	N/A	CorePharma, L.L.C.
Canada	Adrenamate	1,379,772	Pending	January 18, 2008	N/A	CorePharma, L.L.C.
Canada	Adrenomate	1,379,766	Pending	January 18, 2008	N/A	CorePharma, L.L.C.
European Community	Twinject	002542173	002542173	January 21, 2002	February 18, 2004	CorePharma, L.L.C.
European Community	Twinject PD	002603082	002603082	May 3, 2002	October 7, 2003	CorePharma, L.L.C.
European Community	Adrenamate	0951614	0951614	January 16, 2008	January 16, 2008	CorePharma, L.L.C.
European Community	Adrenomate	964833	964833	January 16, 2008	January 16, 2008	CorePharma, L.L.C.
Japan	Twinject	903115	903115	May 26, 2006	May 26, 2006	CorePharma, L.L.C.
Madrid Protocol	Twinject	903115	903115	May 26, 2006	May 26, 2006	CorePharma, L.L.C.
Madrid Protocol	Adrenamate	951614	951614	January 16, 2008	January 16, 2008	CorePharma, L.L.C.
Madrid Protocol	Adrenomate	964833	964833	January 16, 2008	January 16, 2018	CorePharma, L.L.C.
Mexico	Adrenamate	907504	1033825	January 16, 2008	March 31, 2008	CorePharma, L.L.C.
Mexico	Adrenamate	907505	1033826	January 16, 2008	March 31, 2008	CorePharma, L.L.C.
Mexico	Adrenomate	907501	1033823	January 16, 2008	March 31, 2008	CorePharma, L.L.C.
Mexico	Adrenomate	907503	1033824	January 16, 2008	March 31, 2008	CorePharma, L.L.C.

<u>Jurisdiction</u>	<u>Trademark</u>	<u>Application Number</u>	<u>Reg. Number</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Owner</u>
Switzerland	Twinject	903115	903115	May 26, 2006	May 26, 2006	CorePharma, L.L.C.

III. TRADEMARK LICENSES:

SCHEDULE III
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

Copyrights:

- I. COPYRIGHT REGISTRATIONS:
- II. COPYRIGHT APPLICATIONS:
- III. COPYRIGHT LICENSES:

SCHEDULE IV
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

1. Names of each Grantor:

CorePharma, L.L.C.

CorePharma, Inc.

CorePharma Holdings, Inc.

Amedra Pharmaceuticals LLC

2. Office location of each Grantor:

CorePharma, L.L.C.:

215 Wood Ave., Middlesex, New Jersey 08846

CorePharma, Inc.:

215 Wood Ave., Middlesex, New Jersey 08846

CorePharma Holdings, Inc.:

215 Wood Ave., Middlesex, New Jersey 08846

Amedra Pharmaceuticals LLC:

215 Wood Ave., Middlesex, New Jersey 08846

SCHEDULE V
to
INTELLECTUAL PROPERTY SECURITY AGREEMENT

CorePharma, L.L.C.

CorePharma, Inc.

CorePharma Holdings, Inc.

Amedra Pharmaceuticals LLC